Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024)
Inhibikase Therapeutics (IKT) posted quarterly Return on Sales of 204260.85% for Q3 2024, down 20426025.0% year-over-year from N/an in Q4 2023, and down 8444583.18% quarter-over-quarter from 2.42% in Q2 2024.
Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Return on Sales for 5 consecutive years, with 204260.85% the latest figure, recorded in Q3 2024.
- In Q3 2024, Return on Sales fell 20426025.0% year-over-year to 204260.85%; the TTM figure through Sep 2024 stood at 204260.85% (down 20426023.0% YoY), while the FY2023 annual figure was 0.77%, up 170.0% from the prior year.
- Return on Sales declined to 204260.85% in Q3 2024 per IKT's latest filing, from 2.42% in the prior quarter.
- Across five years, Return on Sales topped out at 0.02% in Q1 2021 and bottomed at 204260.85% in Q3 2024.
- Historically, Return on Sales has averaged 13070.69% across 5 years, with a median of 0.68% in 2022.
- Annual changes were most pronounced in 2022 — Return on Sales soared 2516 bps — and 2024, when it sank 20426025 bps.
- Inhibikase Therapeutics' Return on Sales stood at 0.07% in 2020, then tumbled by 36352 bps to 25.84% in 2021, then soared by 97 bps to 0.68% in 2022, then sank by 6457080 bps to 44035.66% in 2023, then tumbled by 364 bps to 204260.85% in 2024.
- Business Quant data shows IKT's Return on Sales at 204260.85% in Q3 2024, 2.42% in Q2 2024, and 1.03% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -204,260.85% |
| Jun 30, 2024 | -2.42% |
| Mar 31, 2024 | -1.03% |
| Dec 31, 2023 | -44,035.66% |
| Sep 30, 2023 | -0.60% |
| Jun 30, 2023 | -0.54% |
| Mar 31, 2023 | -0.74% |
| Dec 31, 2022 | -0.68% |
| Sep 30, 2022 | -6.26% |
| Jun 30, 2022 | -7.08% |
| Mar 31, 2022 | -1.01% |
| Dec 31, 2021 | -25.84% |
| Sep 30, 2021 | -0.14% |
| Jun 30, 2021 | -0.02% |
| Mar 31, 2021 | -0.02% |
| Dec 31, 2020 | -0.07% |
| Sep 30, 2020 | -0.18% |
| Jun 30, 2020 | -0.02% |
| Mar 31, 2020 | -0.02% |